Grifols fully refinances all 2027 maturities following a significantly upsized €3bn Term Loan B

Barcelona, Spain, April 1, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, will successfully refinance its 2027 maturities, both Senior Secured Term Loan B (TLB) and Senior Secured Bonds, with a significantly upsized new Senior Secured TLB of c€3 billion with a seven year maturity and tighter pricing than at launch, strengthening its capital structure and reinforcing its strong positioning in the credit markets, despite the challenged market backdrop.

The transaction attracted strong institutional demand, allowing both USD and euro-denominated tranches to be upsized to c. €3billion equivalent in total, the latter upsized to €1.25 billion from an initial target of €500million.

The U.S. dollar TLB, to be issued by Grifols International Services USA Inc., was priced at SOFR + 250 with an OID of 99.25. The euro tranche was set at Euribor + 300 basis points with an OID of 99.75.

The proceeds will be used on or about the closing date of the transaction to refinance existing TLB maturities due in 2027 and fully repay €740 million of senior secured notes also maturing in 2027, supporting the simplification and extension of the company’s debt maturity profile.

Upon the completion of the TLB, the significantly upsized Revolving Credit Facility (“RCF”) of €1.75 billion equivalent will also become effective. The RCF was supported by a broad syndicate of leading international financial institutions, including BofA, JPMorgan, DNB, Santander, Citi, Commerzbank, Deutsche Bank, Goldman Sachs Bank Europe SE, HSBC, Helaba, UBS, ING, acting as Joint Lead Arrangers and Bookrunners and Nomura as co-manager.

Grifols has been advised by Osborne Clarke, Proskauer Rose LLP and Milbank LLP.

The company’s credit ratings stand at B1 / BB- / BB- at the corporate level and Ba3 / BB- / BB+ for the facility, reflecting the evolution of its financial profile within the current execution phase of its strategic plan.

Rahul Srinivasan, CFO of Grifols, said: “Despite the tricky capital markets backdrop, the overwhelmingly positive response from TLB investors strongly validates both the highly attractive and highly defensive fundamentals of Grifols, facilitating an acceleration of our refinancing plans. We remain very focused on targeting lower cash interest expense and look forward to updating the market in due course.”